Associated Papers
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A et al.
Blood Advances, 2023
36287227 (PubMed )
Supplement: BLOODA_ADV-2022-008447-mmc1.xlsx › Table_S3
Clinical, biochemical, and molecular genetic characteristics of patients with primary carnitine deficiency identified by newborn screening in Shanghai, China.
Chang S et al.
Frontiers in Genetics, 2022
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Katz DA et al.
Clinical Pharmacology and Therapeutics, 2006
MDR1 genotype-related pharmacokinetics and pharmacodynamics.
Sakaeda T et al.
Biological & Pharmaceutical Bulletin, 2002
Select a paper to view details